Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Parallel Advisors LLC

Parallel Advisors LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 37,040 shares of the biopharmaceutical company's stock after selling 2,258 shares during the quarter. Parallel Advisors LLC's holdings in Gilead Sciences were worth $3,421,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership bought a new position in Gilead Sciences in the 4th quarter worth about $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences during the fourth quarter worth approximately $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC boosted its holdings in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 260 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $1.21 during trading hours on Friday, reaching $107.08. The stock had a trading volume of 26,496,290 shares, compared to its average volume of 6,799,971. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market capitalization of $133.35 billion, a PE ratio of 289.41, a PEG ratio of 0.71 and a beta of 0.21. The stock's 50 day moving average is $103.33 and its 200 day moving average is $93.56.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.95%. Gilead Sciences's dividend payout ratio is currently 854.05%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GILD. Oppenheimer lifted their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research report on Tuesday, March 4th. Morgan Stanley lifted their price objective on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a report on Tuesday, March 11th. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a report on Wednesday, February 12th. Piper Sandler upped their price target on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Finally, BMO Capital Markets increased their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $104.52.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $97.22, for a total value of $13,822,739.60. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $12,626,253.06. This trade represents a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 over the last ninety days. Corporate insiders own 0.29% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.